▶ HEXARELIN · SUBTOPIC · SAFETY PROFILE

HEXARELIN Safety Profile

For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of HEXARELIN.

OBSERVED ADVERSE EVENTS IN LITERATURE

The following adverse events have been observed in trials or animal studies of HEXARELIN. Severity, frequency, and attribution depend on the source publication.

Strong appetite stimulation
Cortisol elevation (highest in GHRP class)
Prolactin elevation
Possible GHS-R desensitization with chronic dosing
Injection-site reactions

DRUG INTERACTIONS

The following interactions are reported in or theorised from the published mechanism for HEXARELIN.

Concurrent rhGH not recommended
Glucocorticoids may blunt response

CONTRAINDICATIONS REPORTED IN LITERATURE

Contraindications recorded for HEXARELIN in the published record:

Active malignancy
Pituitary tumor
Pregnancy/lactation

FDA REGULATORY STATUS

Not FDA-approved. Research-use only.

WADA REGULATORY STATUS

Prohibited at all times under WADA Section S2 (growth-hormone-secretagogue sub-category).

SAFETY Q+A FROM LITERATURE

▶ Is hexarelin FDA-approved?

No. Research-use only.

▶ Is hexarelin WADA-prohibited?

Yes. Hexarelin is prohibited at all times under WADA Section S2 in the growth-hormone-secretagogue sub-category.

CITED LITERATURE

The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.

Imbimbo BP, Mant T, Edwards M, et al.. Hexarelin: A new growth hormone-releasing peptide. J Clin Endocrinol Metab 1994. link
Bisi G, Podio V, Valetto MR, et al.. Hexarelin · A new GH-releasing peptide with cardiotropic activity. Eur J Endocrinol 1999. link

◀ HEXARELIN OVERVIEW MECHANISM ▶DOSING LITERATURE ▶

▶ LAST UPDATED · 2026-05-25